Arcutis Biotherapeutics, Inc. (ARQT)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch ARQT
See up to 3 months of ARQT. The 7-day demo opens the 1M and 3M ranges and puts ARQT on your watchlist.
Start 7-day demoLatest ARQT insider trades
- Masaru Matsuda - OfficerOpen-market sale$92K
Howard G. Welgus - Director
About Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. files with the SEC under CIK 0001787306 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
ARQT Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 14 | 90,382 | $2.30M |
| Grant or award | 3 | 38,811 | |
| Option exercise | 28 | 133,120 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ARQT insider transactions (Form 4)
7792 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Masaru Matsuda - Officer | Open-market sale | Common Stock | 3,674 | $25.00 footnote F2 | $92K | |
| ||||||
| Howard G. Welgus - Director | Option exercise | Common Stock | 822 | $6.52 | $5K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 1,019 | $7.51 | $8K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 2,255 | $8.63 | $19K | |
| Howard G. Welgus - Director | Open-market sale | Common Stock | 4,730 | $24.18 | $114K | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 822 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 1,019 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 2,255 | $0.00 | - | |
| Masaru Matsuda - Officer | Open-market sale | Common Stock | 9,989 | $25.03 footnote F2 | $250K | |
| ||||||
| Terrie Curran - Director | Option exercise | Common Stock | 11,148 | $7.51 | $84K | |
| Terrie Curran - Director | Open-market sale | Common Stock | 11,148 | $25.03 footnote F2 | $279K | |
| Terrie Curran - Director | Option exercise | Common Stock | 27,052 | $8.63 | $233K | |
| Terrie Curran - Director | Open-market sale | Common Stock | 27,052 | $25.03 footnote F2 | $677K | |
| Terrie Curran - Director | Option exercise | Stock Option (right to buy) | 11,148 | $0.00 | - | |
| Terrie Curran - Director | Option exercise | Stock Option (right to buy) | 27,052 | $0.00 | - | |
| ||||||
| Terrie Curran - Director | Option exercise | Common Stock | 1,072 | $7.51 | $8K | |
| Terrie Curran - Director | Open-market sale | Common Stock | 1,072 | $26.04 footnote F2 | $28K | |
| Terrie Curran - Director | Option exercise | Stock Option (right to buy) | 1,072 | $0.00 | - | |
| ||||||
| Patrick Burnett - Officer | Open-market sale | Common Stock | 1,697 | $27.00 | $46K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 822 | $6.52 | $5K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 1,019 | $7.51 | $8K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 2,255 | $8.63 | $19K | |
| Howard G. Welgus - Director | Open-market sale | Common Stock | 4,730 | $26.18 footnote F2 | $124K | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 822 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 1,019 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 2,255 | $0.00 | - | |
| ||||||
| Patrick Burnett - Officer | Option exercise | Common Stock | 8,300 | $3.64 | $30K | |
| Patrick Burnett - Officer | Open-market sale | Common Stock | 8,300 | $26.52 footnote F2 | $220K | |
| Patrick Burnett - Officer | Option exercise | Common Stock | 6,700 | $3.64 | $24K | |
| Patrick Burnett - Officer | Open-market sale | Common Stock | 6,700 | $26.08 footnote F3 | $175K | |
| Patrick Burnett - Officer | Option exercise | Stock Option (right to buy) | 8,300 | $0.00 | - | |
| Patrick Burnett - Officer | Option exercise | Stock Option (right to buy) | 6,700 | $0.00 | - | |
| ||||||
| Patrick Burnett - Officer | Open-market sale | Common Stock | 955 | $26.12 footnote F2 | $25K | |
| ||||||
| Masaru Matsuda - Officer | Open-market sale | Common Stock | 1,230 | $26.12 footnote F2 | $32K | |
| ||||||
 Todd Watanabe - Officer | Open-market sale | Common Stock | 4,375 | $26.12 footnote F2 | $114K | |
| ||||||
| Christopher Peetz - Director | Grant or award | Common Stock | 4,315 footnote F1 | $0.00 | - | |
| Christopher Peetz - Director | Grant or award | Stock Option (right to buy) | 21,486 footnote F3 | $0.00 | - | |
| Christopher Peetz - Director | Grant or award | Stock Option (right to buy) | 13,010 footnote F4 | $0.00 | - | |
| ||||||
| Howard G. Welgus - Director | Option exercise | Common Stock | 822 | $6.52 | $5K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 1,019 | $7.51 | $8K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 2,255 | $8.63 | $19K | |
| Howard G. Welgus - Director | Open-market sale | Common Stock | 4,730 | $26.91 | $127K | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 822 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 1,019 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 2,255 | $0.00 | - | |
 Sue-Jean Lin - Director | Open-market sale | Common Stock | 4,946 | $24.38 footnote F2 | $121K | |
| ||||||
| Howard G. Welgus - Director | Option exercise | Common Stock | 2,255 | $8.63 | $19K | |
| Howard G. Welgus - Director | Open-market sale | Common Stock | 4,096 | $24.41 footnote F2 | $100K | |
| Howard G. Welgus - Director | Open-market sale | Common Stock | 635 | $25.67 | $16K | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 822 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 1,019 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Stock Option (right to buy) | 2,255 | $0.00 | - | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 822 | $6.52 | $5K | |
| Howard G. Welgus - Director | Option exercise | Common Stock | 1,019 | $7.51 | $8K | |
| ||||||
| Patrick J. Heron - Director | Grant or award | Common Stock | 5,778 footnote F1 | $0.00 | - | |
| Patrick J. Heron - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| ||||||
| Sue-Jean Lin - Director | Grant or award | Common Stock | 5,778 footnote F1 | $0.00 | - | |
| Sue-Jean Lin - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| ||||||
| Howard G. Welgus - Director | Grant or award | Common Stock | 5,778 footnote F1 | $0.00 | - | |
| Howard G. Welgus - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| ||||||
| Keith R. Leonard - Director | Grant or award | Common Stock | 5,778 footnote F1 | $0.00 | - | |
| Keith R. Leonard - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| ||||||
| Terrie Curran - Director | Grant or award | Common Stock | 5,778 footnote F1 | $0.00 | - | |
| Terrie Curran - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| ||||||
| Amit Munshi - Director | Grant or award | Common Stock | 5,778 footnote F1 | $0.00 | - | |
| Amit Munshi - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| ||||||
| Halley E. Gilbert - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| Halley E. Gilbert - Director | Grant or award | Common Stock | 5,778 footnote F1 | $0.00 | - | |
| ||||||
| Neha Krishnamohan - Director | Grant or award | Common Stock | 5,778 footnote F1 | $0.00 | - | |
| Neha Krishnamohan - Director | Grant or award | Stock Option (right to buy) | 16,667 | $0.00 | - | |
| ||||||
| Latha Vairavan - Officer | Open-market sale | Common Stock | 435 | $21.05 | $9K | |
| Patrick Burnett - Officer | Open-market sale | Common Stock | 222 | $21.05 | $5K | |
| Masaru Matsuda - Officer | Open-market sale | Common Stock | 7,372 | $23.27 footnote F2 | $172K | |
| Masaru Matsuda - Officer | Open-market sale | Common Stock | 884 | $23.61 footnote F5 | $21K | |
| ||||||
| Patrick Burnett - Officer | Open-market sale | Common Stock | 684 | $23.61 footnote F2 | $16K | |
| ||||||
| Latha Vairavan - Officer | Open-market sale | Common Stock | 1,341 | $23.61 footnote F2 | $32K | |
| ||||||
| Todd Watanabe - Officer | Open-market sale | Common Stock | 3,172 | $23.61 footnote F2 | $75K | |
| ||||||
Item 2.02, 5.02, 9.01
Item 5.02, 7.01, 9.01
Item 5.07, 8.01, 9.01
Item 9.01
Recent ARQT Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Larry Todd Edwards | Former Officer | 341,980 | $8.55M | View on EDGAR | |
| Howard Welgus | Director | 4,730 |
Stock trades in ARQT disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Gilbert Ray Cisneros, Jr.Democrat, CA-31 | Purchase |
ARQT insider trading FAQ
What is the latest insider trade for ARQT?
Arcutis Biotherapeutics, Inc. (ARQT) had 13 insider filings in the last 90 days, with the most recent on 2026-09-18. The full record for ARQT runs to 92 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ARQT stock?
No insider purchases of ARQT were filed in the last 90 days. 5 purchases are on record for this company.
How many insiders are selling ARQT stock?
14 insider sales of ARQT were filed in the last 90 days, totaling $2.30M.
Where can I see ARQT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ARQT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Masaru Matsuda view on EDGAR
- - Howard G. Welgus view on EDGAR
- - Masaru Matsuda view on EDGAR
- - Terrie Curran view on EDGAR
- - Terrie Curran view on EDGAR
- - Patrick Burnett view on EDGAR
- - Howard G. Welgus view on EDGAR
- - Patrick Burnett view on EDGAR
- - Patrick Burnett view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ARQT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ARQT with a 7-day demo
- ARQT on your watchlist
- Every ARQT Form 4 filing on record
- Up to 3 months of ARQT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
